PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
13.68%
Cash & equivalents growing 13.68% while RVPH's declined -35.57%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
13.68%
Below half of RVPH's -35.57%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.59%
Below half of RVPH's -24.02%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-11.93%
Both RVPH and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-88.66%
Higher Other Non-Current Assets Growth compared to RVPH's zero value, indicating worse performance.
-8.29%
Both RVPH and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
13.10%
Below half of RVPH's -24.01%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-14.12%
Less than half of RVPH's -53.25%. David Dodd sees a more disciplined AP approach or lower volume.
2.34%
Higher Short-Term Debt Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
14.12%
Higher Deferred Revenue (Current) Growth compared to RVPH's zero value, indicating better performance.
-2.34%
Less than half of RVPH's 94.04%. David Dodd sees fewer expansions in other current obligations.
-12.65%
50-75% of RVPH's -17.36%. Bruce Berkowitz notes the firm keeps current liabilities growth relatively low.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-36.66%
Less than half of RVPH's -75.16%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-14.12%
Less than half of RVPH's 60.69%. David Dodd sees far fewer liability expansions relative to competitor.
5.56%
Higher Common Stock (Book Value) Growth compared to RVPH's zero value, indicating worse performance.
-2.30%
1.25-1.5x RVPH's -1.63%. Bruce Berkowitz notes stronger reinvestment strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.36%
Below half RVPH's -39.21%. Michael Burry sees potential underperformance in building shareholder capital.
13.10%
Below half RVPH's -24.01%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-14.09%
Higher Total Debt Growth compared to RVPH's zero value, indicating worse performance.
-14.00%
Less than half of RVPH's 35.57%. David Dodd sees better deleveraging or stronger cash buildup than competitor.